0.90
-0.98%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ZEO ScientifiX
From its filings with the US Securities and Exchange Commission
ZEO ScientifiX is based in Davie, Florida and is incorporated in Nevada. Its shares trade on OTC under the ticker ZEOX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 October 2025, it reported revenue of $5.2m and a net loss of $5.5m. At that date it held total assets of $1.5m and shareholders' equity of −$1.4m.
We are a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine.
The Company has a portfolio of proprietary products derived from ethically sourced birth tissue, including mesenchymal stem cells, stem cell and amniotic fluid derived exosomes and Whartons Jelly matrix. The Company’s principal product is Zofin™, a product derived from amniotic fluid and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles. ZEO also manufactures Patient Pure X™ (“PPX™”), a proprietary autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood. ZEO’s products are all manufactured in FDA-registered, cGMP-compliant laboratory facilities. Our portfolio of products (“RAAM Products”) and related services are principally used in the health care industry administered through doctors and clinics (“Providers”).
The state of Florida enacted a new “stem cell therapy” law, effective July 1, 2025 (“SB 1768”). The legislation authorizes licensed physicians to administer non-FDA-approved stem cell and other human tissue-derived therapies for orthopedic, wound care, and pain management indications. It mandates compliance with cGMP and prohibits the use of stem cells derived from aborted fetuses, promoting ethically sourced materials such as adult stem cells and umbilical cord blood.
Quoted from its 10-K, filed 29 Jan 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Nov 2013
- Employees
- 20
- Website
- organicell.com ↗
- Head office
- 3321 COLLEGE AVENUE, DAVIE, FL, 33314
- Incorporated in
- NV
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Ian BothwellInterim Chief Executive Officer, Chief Financial Officer, Director, since 2016$324,170
- Mr. Chuck BretzIndependent Non-Executive Vice Chairman of the Board$55,000
- Dr. George ShapiroChief Medical Officer, Director, since 2018$206,154
- Mr. S. Jerry GlauserIndependent Director$380,000
- Mr. Gurvinder SinghIndependent Director$5,000
- Mr. Leathem StearnIndependent Director$255,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zofin (Organicell Flow) contains over 300 growth factors and 102 unique microRNAs for regenerative medicine.
- Organicell Regenerative Medicine Inc has FDA IND and eIND approvals for clinical development.
- The company employs 20 full-time staff in Davie, Florida, focusing on biotechnology research.
Weaknesses
- The company has only 20 employees, limiting operational capacity.
- Zofin is administered through doctors and clinics, restricting direct market access.
- Organicell Regenerative Medicine Inc has no reported revenue or financial data.
Opportunities
- The US biotechnology sector offers growth potential for regenerative medicine therapies.
- FDA approvals could lead to expanded clinical trials and product applications.
- Davie, Florida, provides a strategic location for biotech research and development.
Threats
- The biotechnology industry faces high regulatory hurdles for new drug approvals.
- Competition from established biopharmaceutical companies in the US market.
- Regenerative medicine therapies may face market acceptance challenges due to high costs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.